FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-028
Estimated average b	urden

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					OI	Secu	JII 30(II) C	or trie	mvesuner	II CO	прапу Аст	01 1940								
1. Name and Address of Reporting Person*  BRISSON MARY CATHERINE				2. Issuer Name <b>and</b> Ticker or Trading Symbol Stellar Biotechnologies, Inc. [SBOT]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner							
														X	Officer	(give title		Other (s		
(Last) (First) (Middle)					3. [	Date of Earliest Transaction (Month/Day/Year)									below) below)					
C/O STELLAR BIOTECHNOLOGIES, INC.					12/	12/22/2015								Chief Operating Officer						
332 EAS	ST SCOTT S	STREET																		
(Street)					4. 1	f Ame	ndment, [	Date o	of Original	Filed	(Month/Da	ay/Year)		. Indi	vidual or J	loint/Group	Filing	(Check App	olicable	
PORT	C	Δ.	02041										٦	X	Form f	led by One	Repo	orting Persor	1	
HUENE	ME C.	A	93041														e than	One Repor	ting	
															Persor					
(City)	(S	tate)	(Zip)																	
		Tab	le I - Non	-Deriva	ative	e Se	curities	s Ac	quired,	Dis	posed o	of, or Be	neficia	ally	Owned					
1. Title of Security (Instr. 3)  2. Transa Date (Month/D						ear) i	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Of Code (Instr. 5)			ies Acquired (A) o Of (D) (Instr. 3, 4 a		and Securitie		es Form ally (D) (Following (I) (I		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	Amount (A) or (D)		•	Transact (Instr. 3 a	ion(s)			Instr. 4)	
		-	Table II - I (	Derivat e.g., pı	tive : uts,	Secu calls	urities <i>i</i> s, warra	Acq ants	uired, C , optior	isp is, c	osed of, converti	, or Ben ble secu	eficial urities	ly C	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Ti	4. Transaction Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		[	B. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				С	ode	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amour or Number of Shares	er						
Share Option (Right to Buy)	\$7.24	12/22/2015			A		10,000		(1)		12/18/2022	Common Shares	10,00	0	\$0	10,000		D		

## **Explanation of Responses:**

1. Option grant under the 2013 Fixed Share Option Plan (the "Plan"), which shall vest as to one-third immediately, as to one-third on December 22, 2016 and as to the remaining one-third on June 22, 2017.

/s/ Kathi Niffenegger, as

12/23/2015

Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.